Review top news and interview highlights from the week ending April 15, 2022.
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
While the lower IV dose was generally well-tolerated, the higher dose yielded cases of serious cytokine release syndrome.
The decision was based on findings from the phase 1 TRANSCEND NHL 001 clinical trial.
The novel regimen from BioNTech demonstrated encouraging results in patients with testicular or ovarian cancer.
AFM13 is currently also being evaluated on its own in lymphoma in a phase 2 registrational study.
Erandi De Silva, PhD, co-founder and senior vice president of product development at Forge Biologics, discusses the dual approach of her company in manufacturing and also developing adeno-associated viral-based gene therapies, including FBX-101 for Krabbe disease.